For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Tesamorelin

Also known as: Egrifta

Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.

Real-time market data

Pricing for Tesamorelin

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$8.91/mg

range $3.40–$76.50/mg

Sellers

85

from $0.00

45-day trend

-14.4%

vs 45-day avg $/mg

79 of 85 sellers have a current price· 45 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Tesamorelin

259 third-party tests across 34 vendors. Each card links to the full report.

All 259 COAs for Tesamorelin →
Measured purity 98.0%–100.0% across 147 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.60 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM-13

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Optima Supply· batch OS-2026-1763

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Hydro Research Peptides· batch HR-2026-4509

Aggregated · 3rd-party listing
99.97 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch tsm20-04

Aggregated · 3rd-party listing
99.91 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Profound Aminos· batch Black Cap

✓ Vendor-published
99.83 %
Jun 2026
TrustPointe Analytics Moderate

For

Tesamorelin

by Peptide Partners· batch TES202607

COA on file
Aggregated · 3rd-party listing
99.89 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10-06022026

Aggregated · 3rd-party listing
99.81 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Peptide Plugs· batch 136-02-SM-WT

Aggregated · 3rd-party listing
99.37 %
Jun 2026
Horizon Analytical

For

Tesamorelin

by Blank Peptides· batch B-3699671-P

Aggregated · 3rd-party listing
99.78 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10.05.28.26

Aggregated · 3rd-party listing
99.26 %
Jun 2026
Janoshik Analytical Limited

For

Tesamorelin

by Verified Peptides· batch TM07261020J

✓ Vendor-published
99.89 %
Jun 2026
ILS Laboratories

For

Tesa

by Ion Peptide· batch TSM10-06022026

COA on file
✓ Vendor-published
99.71 %
May 2026
TrustPointe Analytics Moderate

For

Tesamorelin

by Peptide Partners· batch SPL-3947

COA on file
Aggregated · 3rd-party listing
99.00 %
May 2026
Ethos Analytics Strong · HPLC

For

Tesamorelin

by OROS Research· batch OR-LPTES5-526-B6

✓ Vendor-published
99.82 %
May 2026
Kovera Labs

For

Tesamorelin

by Ion Peptide· batch TSM20-05142026

COA on file
Aggregated · 3rd-party listing
99.77 %
May 2026
ILS Labs Strong · HPLC

For

Tesamorelin

by Glacier Aminos· batch TES10GA-07

Aggregated · 3rd-party listing
99.47 %
May 2026
ILS Labs Strong · HPLC

For

Tesamorelin

by Crush Research· batch CR-TSM20-0307-1

Aggregated · 3rd-party listing
99.24 %
May 2026
Janoshik Analytical Limited · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-10-002

Aggregated · 3rd-party listing
99.23 %
May 2026
Janoshik Analytical Limited · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-20-004

✓ Vendor-published
99.02 %
May 2026
Vanguard Laboratory Strong

For

Tesamorelin/Ipamorelin

by Licensed Peptides· batch Green Cap

COA on file
Aggregated · 3rd-party listing
99.48 %
May 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM20-3

✓ Vendor-published
99.43 %
May 2026
FreedomDiagnosticsTesting.com

For

Tesamorelin

by Forge Performance Co.· batch Clear Blue Cap

COA on file
Aggregated · 3rd-party listing
99.78 %
May 2026
ILS Labs Strong

For

Tesamorelin

by Ion Peptide· batch TSM10-05042026

✓ Vendor-published
99.78 %
May 2026
ILS Laboratories

For

Tesamorelin

by Ion Peptide· batch TSMH10-0504206

COA on file
Research depth

23 citations indexed for Tesamorelin

All research on Tesamorelin →

Study · 2026

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol

Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.

case-report · 2026

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists

Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).

animal · 2026

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model

The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.

meta-analysis · 2026

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

Study · 2026

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants